This document is available in three
formats: this web page (for browsing content), PDF (comparable to original document formatting), and
WordPerfect. To view the PDF you will need
Acrobat Reader, which may be downloaded from the Adobe site. For an official signed copy, please contact the
Antitrust Documents Group.

WHEREAS, Plaintiff, United States of America, filed its Complaint on January 24, 2008,
and the United States and Defendants, Pearson plc and Pearson Education Inc. (collectively
"Pearson") and Reed Elsevier PLC, Reed Elsevier NV, and Harcourt Assessment Inc.
(collectively "Reed Elsevier"), by their respective attorneys, have consented to the entry of this
Final Judgment without trial or adjudication of any issue of fact or law, and without this Final
Judgment constituting any evidence against or admission by any party regarding any issue of fact
or law;

AND WHEREAS, Defendants agree to be bound by the provisions of this Final Judgment
pending its approval by the Court;

AND WHEREAS, the essence of this Final Judgment is the prompt and certain
divestiture of certain rights or assets by the Defendants to assure that competition is not
substantially lessened;

AND WHEREAS, the United States requires Defendants to make certain divestitures for
the purpose of remedying the loss of competition alleged in the Complaint;

AND WHEREAS, Defendants have represented to the United States that the divestitures
required below can and will be made and that Defendants will later raise no claim of hardship or
difficulty as grounds for asking the Court to modify any of the divestiture provisions contained
below;

NOW THEREFORE, before any testimony is taken, without trial or adjudication of any
issue of fact or law, and upon consent of the parties, it is ORDERED, ADJUDGED AND
DECREED:

I. Jurisdiction

This Court has jurisdiction over the subject matter and each of the parties to this action.
The Complaint states a claim upon which relief may be granted against Defendants under Section
7 of the Clayton Act, as amended (15 U.S.C. § 18).

II. Definitions

As used in this Final Judgment:

A. "Pearson" means Defendants Pearson plc, a U.K. corporation with its
headquarters in London, England, and Pearson Education Inc., a Delaware corporation with its
headquarters in Upper Saddle River, New Jersey, and includes their successors and assigns, and
their subsidiaries, divisions, groups, affiliates, partnerships, and joint ventures, and their
directors, officers, managers, agents, and employees.

B. "Reed Elsevier" means Defendants Reed Elsevier PLC, a U.K. corporation with
its headquarters in London, England, Reed Elsevier NV, a Dutch corporation with its
headquarters in Amsterdam, Netherlands, and Harcourt Assessment Inc., ("Harcourt") a New
York corporation with its headquarters in San Antonio, Texas and includes their successors and
assigns, and their subsidiaries, divisions, groups, affiliates, partnerships, and joint ventures, and
their directors, officers, managers, agents, and employees.

D. "Speech and Language Assets" means (1) Pearson's Comprehensive Assessment
of Spoken Language, ("CASL") which is in its first edition ("CASL Assets") and Pearson's Oral
and Written Language Scales ("OWLS"), including the Oral Expression and Listening
Comprehension Scales, the Written Expression Scale, and the OWLS second edition, which is
under development (collectively "OWLS Assets") or (2) Reed Elsevier's Clinical Evaluation of
Language Fundamentals ("CELF") including the first-, second-, third-, and fourth-edition titles,
the CELF Screener first-, second-, third-, and fourth-edition titles, the CELF Preschool first-, and
second-edition titles, the CELF Spanish first-, second-, third-, and fourth-edition titles, and the
CELF Spanish Preschool, which is under development; excluding however, the Retained CMS
and WMS Content (collectively "CELF Assets").

all tangible assets that comprise each of the Divestiture Assets including, but not
limited to, all historic and current research data and activities and development
activities relating to the Divestiture Assets; all original and digital artwork, film
plates and other reproductive materials relating to the Divestiture Assets
including, but not limited to, all manuscripts, illustrations, any other content, and
any revisions or revision plans thereof in print or digital form; all finished
inventory of the Divestiture Assets including, but not limited to, all examination
kits, manuals, test booklets, record forms, and response booklets; all contracts,
agreements, commitments, certifications, and understandings relating to the
Divestiture Assets, including, but not limited to, publishing agreements, author
agreements, research agreements, author permissions and other similar
agreements, supply and distribution agreements for the Divestiture Assets; all
customer lists, contracts, accounts, and credit records or similar records of all
sales and potential sales of the Divestiture Assets; all sales support and
promotional materials, advertising materials, and production, sales and marketing
files, and all other records relating to the Divestiture Assets;

all intangible assets used in the development, production, servicing, sale and distribution of each of the Divestiture Assets, including, but not limited to, all
patents, licenses and sublicenses, adaptation licenses, intellectual property,
copyrights, contract rights, trademarks (registered and unregistered), trade names,
service marks, and service names relating to the Divestiture Assets, but excluding
corporate-level trademarks of Pearson and Harcourt; all technical information,
computer software and related documentation, know-how, trade secrets, drawings,
blueprints, designs, design protocols, scoring rules, scoring algorithms, and
specifications for materials relating to the Divestiture Assets; all quality assurance
and control procedures, design tools and simulation capability relating to the
Divestiture Assets; all manuals and technical information used for any purpose
relating to the Divestiture Assets or that Defendants provide to their own
employees, customers, suppliers, agents or licensees for use in relation with the
Divestiture Assets; and all other intangible research data concerning historic and
current research and development efforts relating to the Divestiture Assets,
including, but not limited to, designs of experiments, and the results of successful
and unsuccessful designs and experiments;

the OWLS Assets also specifically include all tangible assets relating to the
development of the OWLS second-edition titles including, but not limited to, all
research data and development activities; all tryout and standardization easels,
administration materials, record forms, tryout data, standardization data, and data
for reliability and validity studies;

the EAS Assets also specifically include all tangible and intangible assets relating
to the development of the EAS including, but not limited, to all research data and
development activities; all tryout and standardization easels, administration
materials, record forms, tryout data, standardization data, and data for reliability
and validity studies; and all algorithmic data including, but not limited to, data
relating to item banking, continuous item rotation, item analysis, item calibration,
norming, test equating, scale development, computer-based testing, and computer-adaptive testing; and all applications of Sampling Theory, the Generalized Graded
Unfolding model, Generalizability Theory model, Structural Equation model, and
other Item Response Theory models;

a royalty-free license to the Acquirer(s) of the ABAS Assets and CELF Assets to
use the Harcourt corporate trademark and trade name for the sole and limited
purpose of distributing finished inventory of the ABAS Assets and CELF Assets;

at the option of the Acquirer(s) of the ABAS Assets and CELF Assets, a non-exclusive license to distribute the Scoring Assistant Software for use with the
ABAS Assets and CELF Assets; and in the event that the Acquirer exercises such
option, the Defendants shall provide to the Acquirer(s) of the ABAS Assets and
CELF Assets all technical information and support necessary for the distribution
and administration of the Scoring Assistant Software;

a royalty-free license to the Acquirer of the CASL Assets and OWLS Assets to
use the Pearson corporate trademark and trade name for the sole and limited
purpose of distributing finished inventory of the CASL Assets and OWLS Assets;

at the option of the Acquirer of the CASL Assets and OWLS Assets, a non-exclusive license to distribute the ASSIST Software for use with the CASL Assets
and OWLS Assets; and in the event that the Acquirer exercises such option, the
Defendants shall provide to the Acquirer of the CASL Assets and OWLS Assets
all technical information and support necessary for the distribution and
administration of the ASSIST Software; and

a license to the Acquirer of the CELF Assets to use the Retained CMS and WMS
Content to market, sell or distribute any tests produced by the CELF Assets.

G. "Acquirer" or "Acquirers" means the entity or entities to whom Defendants divest
the Divestiture Assets.

J. "Licensed-Back ABAS Content" means the two hundred and forty one (241)
ABAS items described in Exhibit A that, as of the filing of the Complaint in this matter, are also
employed in the marketing, sale, and distribution of Reed Elsevier's Bayley Scales of Infant and
Toddler Development second- and third-edition titles.

K. "Retained CMS and WMS Content" means the fifty (50) Children's Memory
Scale ("CMS") and Wechsler Memory Scale ("WMS") items that, as of the filing of the
Complaint in this matter, are also employed in the marketing, sale, and distribution of the CELF
Assets appearing as the Number Repetition 1 (15 items) and Familiar Sequences 1 (12 items)
subtests of the CELF-4, which are borrowed from the Numbers and Sequences CMS subtests,
respectively, and Number Repetition 2 (15 items) and Familiar Sequences 2 (8 items) subtests of
the CELF-4, which are borrowed from the Digit Span and Mental Control WMS subtests,
respectively.

III. Applicability

A. This Final Judgment applies to Pearson and Reed Elsevier, as defined above, and
all other persons in active concert or participation with any of them who receive actual notice of
this Final Judgment by personal service or otherwise.

B. If, prior to complying with Sections IV and V of this Final Judgment, Defendants
sell or otherwise dispose of all or substantially all of their assets or of lesser business units that
include the Divestiture Assets, they shall require the purchaser to be bound by the provisions of
this Final Judgment. Defendants need not obtain such an agreement from the Acquirer(s) of the
Divestiture Assets pursuant to this Final Judgment.

IV. Divestitures

A. Defendants are ordered and directed, within ninety (90) calendar days after the
filing of the Complaint in this matter, or five (5) calendar days after notice of the entry of this
Final Judgment by the Court, whichever is later, to divest the Divestiture Assets in a manner
consistent with this Final Judgment to one or more Acquirers acceptable to the United States, in
its sole discretion. The United States, in its sole discretion, may agree to one or more extensions
of this time period not to exceed sixty (60) calendar days in total, and shall notify the Court in
such circumstances. Defendants agree to use their best efforts to divest the Divestiture Assets as
expeditiously as possible.

B. In accomplishing the divestitures ordered by this Final Judgment, Defendants
promptly shall make known, by usual and customary means, the availability of the Divestiture
Assets. Defendants shall inform any person making inquiry regarding a possible purchase of the
Divestiture Assets that they are being divested pursuant to this Final Judgment and provide that
person with a copy of this Final Judgment. Defendants shall offer to furnish to all prospective
Acquirers, subject to customary confidentiality assurances, all information and documents
relating to the Divestiture Assets customarily provided in a due diligence process except such
information or documents subject to the attorney-client privilege or work-product doctrine.
Defendants shall make available such information to the United States at the same time that such
information is made available to any other person.

C. Defendants shall provide the Acquirer(s) and the United States the identity of any
personnel responsible for any editorial content of any Divestiture Asset, and any personnel
responsible for the sale, development, production, design, layout, standardization, norming,
analysis, or research relating to any of the Divestiture Assets, to enable the Acquirer(s) to make
offers of employment. Defendants will not interfere with any negotiations or attempts by the
Acquirer(s) to employ or contract with any persons responsible for any such activity related to
any Divestiture Asset.

D. Defendants shall permit prospective Acquirers of the Divestiture Assets to have
reasonable access to personnel responsible for the Divestiture Assets; and to have access to any
and all financial, operational, or other documents and information customarily provided as part of
a due diligence process.

E. Defendants shall have the right to obtain, from the Acquirer of the ABAS assets, a
license to use the Licensed-Back ABAS Content for a period of time no longer than is necessary
for Defendants to market, sell or distribute Reed Elsevier's Bayley Scales of Infant and Toddler
Development second- and third-edition titles; such license shall be subject to final review and
approval by the United States.

F. To the extent Defendants receive any orders or inquiries for the ABAS, the CASL,
the OWLS, or the CELF, and an Acquirer has obtained the Divestiture Assets relating to such
test, Defendants shall forward such orders and inquiries to the respective Acquirer for a period of
time not to exceed two (2) years.

G. Defendants shall warrant to the respective Acquirer or Acquirers of the ABAS
Assets, the CASL Assets and OWLS Assets, and the CELF Assets, that the respective Divestiture
Assets will be operational on the date of sale. Defendants shall warrant to the Acquirer of the
EAS Assets that the EAS Assets have been developed in a manner no less vigorous than existing
development plans, as of the filing of the Complaint in this matter, and maintained in a manner
that has preserved the economic viability of the assets, and that, upon divestiture, Acquirer will
receive good title to all the assets that comprise the EAS Assets as of the date of sale.
Defendants shall warrant to the Acquirer or Acquirers that the Divestiture Assets they acquire
have been maintained and operated separately in a manner as required under the Hold Separate
Stipulation and Order ("Hold Separate") filed simultaneously with the Court.

H. Nothing in this Final Judgment shall be construed to require the Acquirer or
Acquirers as a condition of any license granted by or to Defendants pursuant to Sections II (F)(6),
(8), and (9) and IV (E) to extend to Defendants the right to use any improvements made by the
Acquirer or Acquirers to any software or content used in the marketing, sale or distribution of
clinical tests.

I. Defendants shall not take any action that will impede in any way the operation or
divestiture of the Divestiture Assets.

J. Unless the United States otherwise consents in writing, the divestitures pursuant
to Section IV, or by trustee appointed pursuant to Section V, of this Final Judgment, shall include
the entire Divestiture Assets, and shall be accomplished in such a way as to satisfy the United
States, in its sole discretion, that the Divestiture Assets can and will be used by the Acquirer(s) as
part of a viable, ongoing business of publishing clinical tests. Divestiture of the Divestiture
Assets may be made to one or more Acquirers, provided that in each instance it is demonstrated
to the sole satisfaction of the United States that the Divestiture Assets will remain viable and the
divestiture of such assets will remedy the competitive harm alleged in the Complaint. The
divestitures, whether pursuant to Section IV or Section V of this Final Judgment,

shall be made to an Acquirer(s) that, in the United States's sole
judgment, has the intent and capability (including the necessary
managerial, operational, technical and financial capability) of
competing effectively in the business of publishing clinical tests;
and

shall be accomplished so as to satisfy the United States, in its
sole discretion, that none of the terms of any agreement between
an Acquirer(s) and Defendants give Defendants the ability
unreasonably to raise the Acquirer's costs, to lower the
Acquirer's efficiency, or otherwise to interfere in the ability of
the Acquirer to compete effectively.

V. Appointment of Trustee

A. If Defendants have not divested the Divestiture Assets within the time period
specified in Section IV(A), Defendants shall notify the United States of that fact in writing.
Upon application of the United States, the Court shall appoint a trustee selected by the United
States and approved by the Court to effect the divestiture of the Divestiture Assets.

B. After the appointment of a trustee becomes effective, only the trustee shall have
the right to sell the Divestiture Assets. The trustee shall have the power and authority to
accomplish the divestiture to an Acquirer(s) acceptable to the United States at such price and on
such terms as are then obtainable upon reasonable effort by the trustee, subject to the provisions
of Sections IV, V, and VI of this Final Judgment, and shall have such other powers as this Court
deems appropriate. Subject to Section V(D) of this Final Judgment, the trustee may hire at the
cost and expense of Defendants any investment bankers, attorneys, or other agents, who shall be
solely accountable to the trustee, reasonably necessary in the trustee's judgment to assist in the
divestitures.

C. Defendants shall not object to a sale by the trustee on any ground other than the
trustee's malfeasance. Any such objections by Defendants must be conveyed in writing to the
United States and the trustee within ten (10) calendar days after the trustee has provided the
notice required under Section VI.

D. The trustee shall serve at the cost and expense of Defendants, on such terms and
conditions as the United States approves, and shall account for all monies derived from the sale
of the assets sold by the trustee and all costs and expenses so incurred. After approval by the
Court of the trustee's accounting, including fees for its services and those of any professionals
and agents retained by the trustee, all remaining money shall be paid to Defendants and the trust
shall then be terminated. The compensation of the trustee and any professionals and agents
retained by the trustee shall be reasonable in light of the value of the Divestiture Assets and
based on a fee arrangement providing the trustee with an incentive based on the price and terms
of the divestiture and the speed with which it is accomplished, but timeliness is paramount.

E. Defendants shall use their best efforts to assist the trustee in accomplishing the
required divestitures. The trustee and any consultants, accountants, attorneys, and other persons
retained by the trustee shall have full and complete access to the personnel, books, records, and
facilities of the business to be divested, and Defendants shall develop financial and other
information relevant to such business as the trustee may reasonably request, subject to reasonable
protection for trade secret or other confidential research, development, or commercial
information. Defendants shall take no action to interfere with or to impede the trustee's
accomplishment of the divestitures.

F. After its appointment, the trustee shall file monthly reports with the United States
and the Court setting forth the trustee's efforts to accomplish the divestitures ordered under this
Final Judgment. To the extent such reports contain information that the trustee deems
confidential, such reports shall not be filed in the public docket of the Court. Such reports shall
include the name, address, and telephone number of each person who, during the preceding
month, made an offer to acquire, expressed an interest in acquiring, entered into negotiations to
acquire, or was contacted or made an inquiry about acquiring, any interest in the Divestiture
Assets, and shall describe in detail each contact with any such person. The trustee shall maintain
full records of all efforts made to divest the Divestiture Assets.

G. If the trustee has not accomplished the divestitures ordered under this Final
Judgment within six months after its appointment, the trustee shall promptly file with the Court a
report setting forth (1) the trustee's efforts to accomplish the required divestitures, (2) the
reasons, in the trustee's judgment, why the required divestitures have not been accomplished, and
(3) the trustee's recommendations. To the extent such reports contain information that the
trustee deems confidential, such reports shall not be filed in the public docket of the Court. The
trustee shall at the same time furnish such report to the United States which shall have the right
to make additional recommendations consistent with the purpose of the trust. The Court
thereafter shall enter such orders as it shall deem appropriate to carry out the purpose of the Final
Judgment, which may, if necessary, include extending the trust and the term of the trustee's
appointment by a period requested by the United States.

VI. Notice of Proposed Divestitures

A. Within two (2) business days following execution of a definitive divestiture
agreement, Defendants or the trustee, whichever is then responsible for effecting the divestitures
required herein, shall notify the United States of any proposed divestiture required by Section IV
or V of this Final Judgment. If the trustee is responsible, it shall similarly notify Defendants.
The notice shall set forth the details of the proposed divestiture and list the name, address, and
telephone number of each person not previously identified who offered or expressed an interest
in or desire to acquire any ownership interest in the Divestiture Assets, together with full details
of the same.

B. Within fifteen (15) calendar days of receipt by the United States of such notice,
the United States may request from Defendants, the proposed Acquirer(s), any other third party,
or the trustee, if applicable, additional information concerning the proposed divestiture, the
proposed Acquirer, and any other potential Acquirer. Defendants and the trustee shall furnish
any additional information requested within fifteen (15) calendar days of the receipt of the
request, unless the parties shall otherwise agree.

C. Within thirty (30) calendar days after receipt of the notice or within twenty (20)
calendar days after the United States has been provided the additional information requested
from Defendants, the proposed Acquirer, any third party, and the trustee, whichever is later, the
United States shall provide written notice to Defendants and the trustee, if there is one, stating
whether or not it objects to the proposed divestiture. If the United States provides written notice
that it does not object, the divestiture may be consummated, subject only to Defendants' limited
right to object to the sale under Section V(C) of this Final Judgment. Absent written notice that
the United States does not object to the proposed Acquirer or upon objection by the United
States, a divestiture proposed under Section IV or Section V shall not be consummated. Upon
objection by Defendants under Section V(C), a divestiture proposed under Section V shall not be
consummated unless approved by the Court.

VII. Financing

Defendants shall not finance all or any part of any purchase made pursuant to Section IV
or V of this Final Judgment.

VIII. Hold Separate

Until the divestitures required by this Final Judgment have been accomplished,
Defendants shall take all steps necessary to comply with the Hold Separate entered by this Court.
Defendants shall take no action that would jeopardize the divestitures ordered by this Court.

IX. Affidavits

A. Within twenty (20) calendar days of the filing of the Complaint in this matter, and
every thirty (30) calendar days thereafter until the divestitures have been completed under
Section IV or V, Defendants shall deliver to the United States an affidavit as to the fact and
manner of its compliance with Section IV or V of this Final Judgment. Each such affidavit shall
include the name, address, and telephone number of each person who, during the preceding thirty
(30) calendar days, made an offer to acquire, expressed an interest in acquiring, entered into
negotiations to acquire, or was contacted or made an inquiry about acquiring, any interest in the
Divestiture Assets, and shall describe in detail each contact with any such person during that
period. Each such affidavit shall also include a description of the efforts Defendants have taken
to solicit buyers for the Divestiture Assets, and to provide required information to prospective
Acquirers, including the limitations, if any, on such information. Assuming the information set
forth in the affidavit is true and complete, any objection by the United States to information
provided by Defendants, including limitation on information, shall be made within fourteen (14)
calendar days of receipt of such affidavit.

B. Within twenty (20) calendar days of the filing of the Complaint in this matter,
Defendants shall deliver to the United States an affidavit that describes in reasonable detail all
actions Defendants have taken and all steps Defendants have implemented on an ongoing basis to
comply with Section VIII of this Final Judgment. Defendants shall deliver to the United States
an affidavit describing any changes to the efforts and actions outlined in Defendants' earlier
affidavits filed pursuant to this section within fifteen (15) calendar days after the change is
implemented.

C. Defendants shall keep all records of all efforts made to preserve and divest the
Divestiture Assets until one year after such divestitures have been completed.

X. Compliance Inspection

A. For the purposes of determining or securing compliance with this Final Judgment,
or of determining whether the Final Judgment should be modified or vacated, and subject to any
legally recognized privilege, from time to time authorized representatives of the United States
Department of Justice, including consultants and other persons retained by the United States,
shall, upon written request of an authorized representative of the Assistant Attorney General in
charge of the Antitrust Division, and on reasonable notice to Defendants, be permitted:

access during Defendants' office hours to inspect and copy, or at the
option of the United States, to require Defendants to provide hard copy or
electronic copies of, all books, ledgers, accounts, records, data, and
documents in the possession, custody, or control of Defendants, relating to
any matters contained in this Final Judgment; and

to interview, either informally or on the record, Defendants' officers,
employees, or agents, who may have their individual counsel present,
regarding such matters. The interviews shall be subject to the reasonable
convenience of the interviewee and without restraint or interference by
Defendants.

B. Upon the written request of an authorized representative of the Assistant Attorney
General in charge of the Antitrust Division, Defendants shall submit written reports or response
to written interrogatories, under oath if requested, relating to any of the matters contained in this
Final Judgment as may be requested.

C. No information or documents obtained by the means provided in this section shall
be divulged by the United States to any person other than an authorized representative of the
executive branch of the United States, except in the course of legal proceedings to which the
United States is a party (including grand jury proceedings), or for the purpose of securing
compliance with this Final Judgment, or as otherwise required by law.

D. If at the time information or documents are furnished by Defendants to the United
States, Defendants represent and identify in writing the material in any such information or
documents to which a claim of protection may be asserted under Rule 26(c)(7) of the Federal
Rules of Civil Procedure, and Defendants mark each pertinent page of such material, "Subject to
claim of protection under Rule 26(c)(7) of the Federal Rules of Civil Procedure," then the United
States shall give Defendants ten (10) calendar days notice prior to divulging such material in any
legal proceeding (other than a grand jury proceeding).

XI. No Reacquisition

Pearson may not reacquire any part of the Divestiture Assets during the term of this Final
Judgment.

XII. Retention of Jurisdiction

This Court retains jurisdiction to enable any party to this Final Judgment to apply to this
Court at any time for further orders and directions as may be necessary or appropriate to carry out
or construe this Final Judgment, to modify any of its provisions, to enforce compliance, and to
punish violations of its provisions.

XIII. Expiration of Final Judgment

Unless this Court grants an extension, this Final Judgment shall expire ten years from the
date of its entry.

XIV. Public Interest Determination

Entry of this Final Judgment is in the public interest. The parties have complied with the
requirements of the Antitrust Procedures and Penalties Act, 15 U.S.C. § 16, including making
copies available to the public of this Final Judgment, the Competitive Impact Statement, and any
comments thereon and the United States's responses to comments. Based upon the record before
the Court, which includes the Competitive Impact Statement and any comments and response to
comments filed with the Court, entry of this Final Judgment is in the public interest.

The Licensed-Back ABAS Content includes all of the items appearing in the ABAS-II
Parent/Primary Caregiver (Ages 0-5) that, as of the filing of the Complaint in this matter, also
appear as the Adaptive Behavior Scale subtest in Reed Elsevier's Bayley Scales of Infant and
Toddler Development ("Bayley-III"). Specifically, the shared content includes all items in the
following scales: Communication, Community Use, Functional Pre-Academics, Home Living,
Health and Safety, Leisure, Self-Care, Self-Direction, Social, and Motor.

In addition to the shared items, the shared content within the scales listed above also
includes the following:

administration instructions and sample items (appearing on pp. 4-5
of the Bayley-III Social-Emotional and Adaptive Behavior
Questionnaire, or the "record form");

record form summary page content and design, including the following tables:
raw-score to scaled-score conversions, sum of scaled scores to composite-score
conversions, skill area scaled score profile, composite score profile and
supplemental analysis — discrepancy comparisons (appearing on page 14 of the
Bayley-III Social Emotional and Adaptive Behavior Questionnaire);